Buprenorphine and Telehealth: A New Era in Opioid Use Disorder Treatment

By Staff Writer

August 7, 2023

Buprenorphine, the most frequently prescribed medication for opioid use disorder (OUD), is used to treat an estimated 1 to 2 million individuals annually. It’s a first-line treatment for OUD, highly effective at reducing opioid use, overdose, and all-cause mortality, and improving quality of life.

However, routine urine drug screening (UDS) to test for adherence to treatment and illicit substance use is inconsistent, despite its commonality in addiction treatment settings. There is a lack of consensus about testing schedules and how to respond to results, leading to great variation and inconsistencies.

The COVID-19 pandemic has catalysed federal policy changes, allowing for expanded telehealth-based opioid treatment (TBOT). Studies have found that TBOT may be associated with improved patient outcomes relative to in-person treatment. However, there’s an urgent need for rigorous studies exploring UDS in remote care settings.

A recent study found that most patients completed a UDS in the first 30 days of care, and an overwhelming majority within the first 90 days of care, suggesting that drug testing is feasible over a telehealth treatment platform.

Findings suggest that buprenorphine delivered in TBOT settings is an effective treatment for OUD, with low rates of opioid use across all time points in care.

However, the digital divide could exacerbate existing disparities related to health care access. It’s crucial for TBOT platforms to consider the complex interplay between clinical suitability for remote care and socioeconomic and digital barriers.

This is the first study characterising UDS administration and results in an exclusively TBOT setting, a significant step towards identifying the optimal processes for UDS in remote care settings.

Reference url

Recent Posts

elderly care costs 2025
      

Elderly Care Costs 2025: Rising Financial Pressures in Dutch Health Services

💡 Are you prepared for the surge in elderly care costs projected for 2025?

A recent report from Zorginstituut Nederland reveals that the financial burden on the Dutch health system is set to rise significantly due to demographic shifts and increased demand for complex care. As policymakers navigate these challenges, the insights address crucial implications for health economics, reimbursement strategies, and sustainable access to care.

Don’t miss out on understanding how these trends could shape the future of healthcare. Dive into the full article for comprehensive insights!

#SyenzaNews #HealthEconomics #HealthcarePolicy #DigitalTransformation

silencing science impact
      

Silencing Science Impact: Political Interference and Global Health Consequences

🔍 Are political interventions threatening the very foundation of scientific integrity?

A recent article from the BMJ highlights alarming shifts within U.S. governance that are undermining scientific autonomy, equity in health research, and public trust. From funding cuts to the suppression of critical fields like climate science, the implications are far-reaching.

Curious about how these changes may affect the future of healthcare and innovative reimbursement? Dive into the full discussion to understand the stakes and potential solutions.

#SyenzaNews #HealthEconomics #HealthcarePolicy

AAP childhood obesity guidelines
     

Caution Advised: Conflicts in AAP Childhood Obesity Guidelines

Are childhood obesity guidelines driving us toward conflict? 🌍 The recent AAP guidelines suggest weight loss medications for children as young as eight, but undisclosed financial ties to drug manufacturers raise serious questions about credibility.

In this article, we dive into the implications of these conflicts and the evidence gaps surrounding pharmaceutical interventions in pediatric care. Transparency and trust are crucial when it comes to the health of our children—let’s explore what needs to change.

Read more to find out how these guidelines could impact families, clinicians, and healthcare policy.

#SyenzaNews #HealthcareInnovation #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.